Bionano’s Post

Using a phase-appropriate approach, our recombinant off-the-shelf AAV and LVV viral vectors and plasmids make for more simplified gene therapy development. Empower breakthroughs in your discovery phase and start with the end in mind with a complete concept to cure portfolio through Charles River. Empower Your Research: https://okt.to/gV8F9f

Using a phase-appropriate approach, our recombinant off-the-shelf AAV and LVV viral vectors and plasmids make for more simplified gene therapy development. Empower breakthroughs in your discovery phase and start with the end in mind with a complete concept to cure portfolio through Charles River. Empower Your Research: https://okt.to/2YeDB7

Having trouble with preclinical assessments for gene and cell therapies because traditional animal models lack human genes and pathways? Learn how our #PXBmouse and #PXBcells can change that at ASGCT 2024. Book a meeting with our attending team members in the link below. #preclinicalresearch #humanizedmodels

"Trends Shaping the Future of Drug Delivery Vectors" - you don't want to miss this whitepaper by Beckman Coulter Life Sciences. Discover the newest approaches and advancements that are revolutionizing drug delivery: from viral vectors for gene therapy to non-viral alternatives, and from extracellular vesicles as delivery vehicles to smart and stimuli-responsive vectors. Access this invaluable article today! https://lnkd.in/dUgNVQxM #drugdelivery #whitepaper #lnps #evs

Are you looking to improve your understanding of the characteristics of a target product profile (TPP) and learn how to create a robust TPP to increase the likelihood of successful adoption of your #AdvancedTherapy? The Cell and Gene Therapy Catapult are hosting a webinar titled 'Developing a robust target product profile (TPP) for successful therapy adoption' on the 31st January where some of our key experts will be discussing our recently released TPP guide, the importance of a TPP and how to approach building one. Learn more: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #NonClinical

🧪 Lentiviral vs Retroviral – Which Viral Vector Is Right For My Research? 🧬 Our viral vector team breaks down some of the differences between lentivirus and retrovirus when it comes to cell and gene therapy applications, manufacturing differences and similarities, and plasmid DNA requirements between the two vectors. 🧫https://lnkd.in/eZBUnq3T ⚗️ Let's accelerate your team's discovery! 🔬

Join Daniel Forsström, R&D Application and Custom Service Manager, on December 13th for a webinar that will revolutionize your plate-based ELISA assays and take your gene therapy development to the next level. 🚀 You will learn how automating your manual ELISA can save valuable time and resources and boost productivity. Case studies will illustrate how manual ELISA assays for viral titer and impurity analysis can be seamlessly transferred to the automated Gyrolab platform. Save the Date: 🗓️ December 13, 2023 ⏰ Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET 📍https://lnkd.in/dQR299kx Let's unlock the full potential of your research together! 💪 #GeneTherapy #ELISAAssays #GyrolabTechnnology #AutomatedImmunoassays #Webinar #Research #Productivity #Innovation #UnlockPotential

Using a phase-appropriate approach, our recombinant off-the-shelf AAV and LVV viral vectors and plasmids make for more simplified gene therapy development. Empower breakthroughs in your discovery phase and start with the end in mind with a complete concept to cure portfolio through Charles River. Empower Your Research: https://okt.to/gzW4nf

Using a phase-appropriate approach, our recombinant off-the-shelf AAV and LVV viral vectors and plasmids make for more simplified gene therapy development. Empower breakthroughs in your discovery phase and start with the end in mind with a complete concept to cure portfolio through Charles River. Empower Your Research: https://okt.to/KTzQ5e

A great panel discussing an important question. Looking forward to it!